<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920828</url>
  </required_header>
  <id_info>
    <org_study_id>OregonHSU-8833</org_study_id>
    <nct_id>NCT01920828</nct_id>
  </id_info>
  <brief_title>Gait Analysis in MPS IVA</brief_title>
  <official_title>Gait Analysis in Patients With MPS IVA Treated With Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about gait (walking) characteristics in MPS IVA and
      possible changes in gait with enzyme replacement therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this 3-year study is to conduct a longitudinal investigation using motion
      analysis of gait to objectively and quantitatively assess gait characteristics of MPS IVA
      patients.  Data documenting gait characteristics and abnormalities will be gathered in
      patients initiating enzyme replacement therapy.

      Inclusion criteria Individuals with MPS IVA diagnosed by enzyme or molecular studies
      Exclusion Criteria Individual with MPS IVA previously enrolled in BMN-110 Individual is
      non-ambulatory The individual is unable to complete longitudinal study visits at least
      yearly
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Measurable changes in gait</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data acquired on patients will be compared with age-matched standardized norms. The normal data is available from a pre-existing Gait Repository, a collection of gait parameters in children without a specific diagnosis studied at Oregon Health and Science University. The results will be converted to centile charts with the aid of a biostatistician. Centile charts will be used to track statistical changes over time in the following gait parameters including but not exclusive to:  velocity, cadence, step length, and base of support.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>MPS IVA</condition>
  <condition>Morquio Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of MPS IVA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Diagnosis of MPS IVA

        Exclusion Criteria:

        Non-ambulatory

          -  Previous enrolled in clinical trial BMN-110
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Hata, MS CGC</last_name>
      <phone>503-418-1061</phone>
      <email>hata@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Abigail Hata, MS CGC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Abigail Hata</investigator_full_name>
    <investigator_title>Abigail Hata, MS CGC</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
